<DOC>
	<DOCNO>NCT01831505</DOCNO>
	<brief_summary>Many cancer patient prescribe drug cancer already resistant - thus suffer toxicity potential benefit . Previous attempt assess chemoresistance sensitivity vitro fail . This feasibility study human patient newly diagnose recurrent lymphoma determine human cancerous lymph node situ respond standard care therapeutic precisely microinjected CIVO ( tm ) microdosing system .</brief_summary>
	<brief_title>Feasibility Assessing Lymphoma Response Precise Local Injection Candidate Chemotherapy Agents</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>18 year age Has enlarge lymph node ( ) highly suspicious lymphoma ; diagnose lymphoma untreated ; persistent recurrent , progressive lymphoma At least one enlarge lymph node consider accessible percutaneous injection investigator least 2 cm long dimension . ECOG performance status 02 ( Karnofsky performance status &gt; 50 % ) . Labs require enrollment : Absolute neutrophil count &gt; 1000/mm3 , platelet count &gt; 50,000/mm3 , hematocrit &gt; 25 % , creatinine &lt; 3.0 mg/dl , total bilirubin &lt; 4.0 mg/dl , SGOT SGPT less five time institutional upper limit normal . Lymphoma patient delay surgery lymph node resection date factor associate study feasible . Patients central nervous system disease . Any therapy potentially immunosuppressive anticancer activity 4 week prior device microinjection . Patients active fungal , viral , bacterial infection Pregnant woman . Inability give inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>personalize medicine</keyword>
	<keyword>vivo drug sensitivity</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>lymphoma</keyword>
	<keyword>microinjection</keyword>
</DOC>